Literature DB >> 24056114

Colorectal cancer liver metastases: long-term survival and progression-free survival after thermal ablation using magnetic resonance-guided laser-induced interstitial thermotherapy in 594 patients: analysis of prognostic factors.

Thomas J Vogl1, Alena Dommermuth, Britta Heinle, Nour-Eldin A Nour-Eldin, Thomas Lehnert, Katrin Eichler, Stephan Zangos, Wolf O Bechstein, Nagy N N Naguib.   

Abstract

PURPOSE: The purpose of this study was the evaluation of prognostic factors for long-term survival and progression-free survival (PFS) after treatment of colorectal cancer (CRC) liver metastases with magnetic resonance-guided laser-induced interstital thermotherapy (LITT). PATIENTS AND METHODS: We included 594 patients (mean age, 61.2 years) with CRC liver metastases who were treated with LITT. The statistical analysis of the long-term survival and PFS were based on the Kaplan-Meier method. The Cox regression model tested different parameters that could be of prognostic value. The tested prognostic factors were the following: sex, age, the location of primary tumor, the number of metastases, the maximal diameter and total volume of metastases and necroses, the quotient of total volumes of metastases and necroses, the time of appearance of liver metastases and location in the liver, the TNM classification of CRC, extrahepatic metastases, and neoadjuvant treatments.
RESULTS: The median survival was 25 months starting from the date of the first LITT. The 1-, 2-, 3-, 4-, and 5-year survival rates were 78%, 50.1%, 28%, 16.4%, and 7.8%, respectively. The median PFS was 13 months. The 1-, 2-, 3-, 4-, and 5-year PFS rates were 51.3%, 35.4%, 30.7%, 25.4%, and 22.3%, respectively. The number of metastases and their maximal diameter were the most important prognostic factors for both long-term survival and PFS. Long-term survival was also highly influenced by the initial involvement of the lymph nodes.
CONCLUSIONS: For patients treated with LITT for CRC liver metastases, the number and size of metastases, together with the initial lymph node status, are significant prognostic factors for long-term survival.

Entities:  

Mesh:

Year:  2014        PMID: 24056114     DOI: 10.1097/RLI.0b013e3182a6094e

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  13 in total

1.  Functional magnetic resonance imaging response of targeted tumor burden and its impact on survival in patients with hepatocellular carcinoma.

Authors:  Celia Pamela Corona-Villalobos; Vivek Gowdra Halappa; Susanne Bonekamp; John Eng; Diane Reyes; David Cosgrove; Neda Rastegar; Li Pan; Timothy M Pawlik; Ihab R Kamel
Journal:  Invest Radiol       Date:  2015-04       Impact factor: 6.016

2.  Thermal ablation in colorectal liver metastases: Lack of evidence or lack of capability to prove the evidence?

Authors:  Sergio Sartori; Paola Tombesi; Francesca Di Vece
Journal:  World J Gastroenterol       Date:  2016-04-07       Impact factor: 5.742

3.  Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update.

Authors:  Muneeb Ahmed; Luigi Solbiati; Christopher L Brace; David J Breen; Matthew R Callstrom; J William Charboneau; Min-Hua Chen; Byung Ihn Choi; Thierry de Baère; Gerald D Dodd; Damian E Dupuy; Debra A Gervais; David Gianfelice; Alice R Gillams; Fred T Lee; Edward Leen; Riccardo Lencioni; Peter J Littrup; Tito Livraghi; David S Lu; John P McGahan; Maria Franca Meloni; Boris Nikolic; Philippe L Pereira; Ping Liang; Hyunchul Rhim; Steven C Rose; Riad Salem; Constantinos T Sofocleous; Stephen B Solomon; Michael C Soulen; Masatoshi Tanaka; Thomas J Vogl; Bradford J Wood; S Nahum Goldberg
Journal:  Radiology       Date:  2014-06-13       Impact factor: 11.105

4.  Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update.

Authors:  Muneeb Ahmed; Luigi Solbiati; Christopher L Brace; David J Breen; Matthew R Callstrom; J William Charboneau; Min-Hua Chen; Byung Ihn Choi; Thierry de Baère; Gerald D Dodd; Damian E Dupuy; Debra A Gervais; David Gianfelice; Alice R Gillams; Fred T Lee; Edward Leen; Riccardo Lencioni; Peter J Littrup; Tito Livraghi; David S Lu; John P McGahan; Maria Franca Meloni; Boris Nikolic; Philippe L Pereira; Ping Liang; Hyunchul Rhim; Steven C Rose; Riad Salem; Constantinos T Sofocleous; Stephen B Solomon; Michael C Soulen; Masatoshi Tanaka; Thomas J Vogl; Bradford J Wood; S Nahum Goldberg
Journal:  J Vasc Interv Radiol       Date:  2014-10-23       Impact factor: 3.464

Review 5.  Locoregional Therapies of Cholangiocarcinoma.

Authors:  Christof M Sommer; Hans U Kauczor; Philippe L Pereira
Journal:  Visc Med       Date:  2016-12-05

Review 6.  The efficacy of laser interstitial thermal therapy in the management of spinal metastases: a systematic review of the literature.

Authors:  Andrea Cardia; Delia Cannizzaro; Roberto Stefini; Salvatore Chibbaro; Mario Ganau; Ismail Zaed
Journal:  Neurol Sci       Date:  2022-10-01       Impact factor: 3.830

7.  Optimized Echo Decorrelation Imaging Feedback for Bulk Ultrasound Ablation Control.

Authors:  Mohamed A Abbass; Allison-Joy Garbo; Neeraja Mahalingam; Jakob K Killin; T Douglas Mast
Journal:  IEEE Trans Ultrason Ferroelectr Freq Control       Date:  2018-06-14       Impact factor: 2.725

Review 8.  Computed Tomography and Ultrasounds for the Follow-up of Hepatocellular Carcinoma Ablation: What You Need to Know.

Authors:  Alexios Kelekis; Dimitrios Filippiadis
Journal:  Diagnostics (Basel)       Date:  2016-02-04

Review 9.  Combination of ablation and embolization for intermediate-sized liver metastases from colorectal cancer: what can we learn from treating primary liver cancer?

Authors:  Matthew J Seager; Tobias F Jakobs; Ricky A Sharma; Steve Bandula
Journal:  Diagn Interv Radiol       Date:  2021-09       Impact factor: 2.630

Review 10.  Evolving ablative therapies for hepatic malignancy.

Authors:  Smit Singla; Steven N Hochwald; Boris Kuvshinoff
Journal:  Biomed Res Int       Date:  2014-04-29       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.